Explaining phenotype heterogeneity in patients with psoriasis

British Journal of Dermatology

Volumn 158, Issue 3, 2008, Pages 437-441

  Christophers, E ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Phenotype switch; Psoriasis

Indexed keywords

ALPHA INTERFERON; BOPIRIMINE; CYCLOSPORIN; GAMMA INTERFERON; HLA ANTIGEN; HLA CW 0602 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 23; LOXORIBINE; SINGLE STRANDED RNA; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

CLINICAL FEATURE; CONCEPTUAL FRAMEWORK; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; INNATE IMMUNITY; NATURAL KILLER CELL; NEUTROPHIL; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE RECEPTOR GENE;

AGE OF ONSET; COHORT STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-17; MALE; PHENOTYPE; POLYMORPHISM, GENETIC; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 39049135336     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08307.x     Document Type: Review

References (48)

1. Griffiths CEM, Christophers E, Barker JNWN et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007 156 : 258 62.
2. Williams RC, McKenzie AW, Roger JH, Joysey VC. HL-A antigens in patients with guttate psoriasis. Br J Dermatol 1976 95 : 163 87.
3. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985 13 : 450 6.
4. Nair RP, Stuart PE, Nistor I et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006 78 : 827 51.
5. Ferrandiz C, Pujol RM, Garcia-Patos V et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002 46 : 867 73.
6. Gudjonsson JE, Karason A, Antonsdottir AA et al. HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002 118 : 362 5.
7. Mallbris L, Larsson P, Bergqvist S et al. Psoriasis phenotype at disease onset: clinical characterization of 400 adult cases. J Invest Dermatol 2005 124 : 499 504.
8. Gudjonsson JE, Karason A, Runarsdottir AH et al. Distinct clinical differences between HLA-Cw6*0602 positive and negative psoriasis patients - an analysis of 1019 HLA-C and HLA-B-typed patients. J Invest Dermatol 2006 126 : 740 5.
9. Bos JD. The pathomechanism of psoriasis: the skin immune system and cyclosporin. Br J Dermatol 1988 118 : 141 55.
10. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996 98 : 1878 87.
11. Prinz JC. Disease mimicry - a pathogenetic concept for T cell-mediated autoimmune disorders triggered by molecular mimicry. Autoimmun Rev 2004 3 : 10 15.
12. Johnston A, Gudjonsson JE, Sigmundsdottir H et al. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin Exp Immunol 2004 138 : 83 93.
13. Valdimarsson H, Baker B, Jonsdottir I et al. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 1986 7 : 256 9.
14. Schlaak JF, Buslau M, Jochum W et al. T cells involved in psoriasis belong to the Th1 subset. J Invest Dermatol 1994 102 : 145 9.
15. Christophers E. The immunopathology of psoriasis. Int Arch Allergy Immunol 1996 110 : 199 206.
16. Austin LM, Ozawa M, Kikuchi T et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2 and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999 113 : 752 9.
17. Bos JD, de Rie MA, Teunissen MBM, Piskin G. Psoriasis: dysregulation of innate immunity. Br J Dermatol 2005 152 : 1098 107.
18. Schön WP, Boencke WH. Psoriasis. N Engl J Med 2005 352 : 1899 912.
19. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007 445 : 866 73.
20. Nestle FO, Conrad C, Tun-Kyi A et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J Exp Med 2005 202 : 135 43.
21. Wollenberg AM, Wagner S, Gunther S et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002 119 : 1096 102.
22. Liu YC. IPC: professional type I interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005 23 : 275 306.
23. Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007 13 : 242 4.
24. Blauvelt A. New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-β1. Expert Rev Dermatol 2007 2 : 69 78.
25. Hemmi H, Kaisho O, Takeuchi S et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signalling pathway. Nat Immunol 2002 3 : 196 200.
26. Gilliet M, Conrad C, Geiges A et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmocytoid dendritic cell precursors. Arch Dermatol 2004 140 : 1490 5.
27. Lebre MC, van der Aar AMG, van Baarsen L et al. Human keratinocytes express functional toll-like receptors. J Invest Dermatol 2007 127 : 331 41.
28. Langowski JL, Kastelein RA, Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol 2007 28 : 207 12.
29. Lee E, Trepicchio WL, Oestreicher JL et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004 199 : 125 30.
30. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006 167 : 1908 15.
31. Toichi E, Torres G, McCormick TS et al. An anti IL-12p40 antibody downregulates type I cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006 177 : 4917 26.
32. Krueger GG, Langley REG, Leonardi C et al. A human interleukin 12/23 monoclonal antibody for the treatment of plaque psoriasis. N Engl J Med 2007 349 : 580 92.
33. Mannon PJ, Mayer L, Elson CO et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004 351 : 2069 79.
34. Cargill M, Schrodi SJ, Chang M et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007 80 : 273 90.
35. Duerr GD, Taylor KD, Rioux JD et al. Genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006 314 : 1461 3.
36. Zheng Y, Danilenko DM, Valdez P et al. Interleukin-22, a Th17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007 445 : 648 51.
37. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006 27 : 17 23.
38. Sa SM, Valdez PA, Wu J et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007 178 : 2229 40.
39. Schröder JM, Christophers E. Identification of C5a des arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J Invest Dermatol 1986 87 : 53 8.
40. Harder J, Schröder JM. Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. J Leukoc Biol 2005 77 : 476 86.
41. Wolk KE, Witte E, Wallace W-D et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006 36 : 1309 23.
42. Wei CC, Chen WY, Wang YC et al. Detection of IL-20 and its receptors on psoriatic skin. Clin Immunol 2005 117 : 65 72.
43. Boniface K, Bernard FX, Garcia M et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration in human keratinocytes. J Immunol 2005 174 : 3695 702.
44. Gläser E, Harder J, Lange H et al. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat Immunol 2005 6 : 57 64.
45. Schröder JM, Harder J. Antimicrobial peptides and proteins. Cell Mol Life Sci 2006 63 : 469 86.
46. Neurath MF. IL-23: a master regulator in Crohn's disease. Nat Med 2007 13 : 26 8.
47. Gaya DR, Russel RK, Nimma ER, Satsangi J. New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 2006 367 : 1271 84.
48. Yen D, Cheung J, Scheerens H et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006 116 : 1310 16.